Literature DB >> 35263713

Letter: Diabesity Associates with Poor COVID-19 Outcomes among Hospitalized Patients (J Obes Metab Syndr 2021;30:149-54).

Tae Jung Oh1,2.   

Abstract

Entities:  

Year:  2022        PMID: 35263713      PMCID: PMC8987459          DOI: 10.7570/jomes21094

Source DB:  PubMed          Journal:  J Obes Metab Syndr        ISSN: 2508-6235


× No keyword cloud information.
Both diabetes and obesity are related to poor health outcomes of coronavirus disease 2019 (COVID-19). Approximately half of COVID-19 mortalities involved individuals with metabolic and vascular disorders.[1] Therefore, special attention should be paid to this population. A previous meta-analysis[2] including 24 cohort studies showed that odds ratios (ORs) of obesity for intensive care unit admission and invasive mechanical ventilation were 1.21 and 2.05, respectively. However, since obesity and diabetes are inter-related conditions, the effects of diabetes cannot be eliminated when analyzing the impact of obesity in data including both diabetic and non-diabetic subjects. Nikniaz et al.[3] reported useful findings in a paper entitled “Diabesity associates with poor COVID-19 outcomes among hospitalized patients,” which was based on their prospective hospital-based registry of COVID-19 patients in East Azerbaijan, the Iranian province with the highest prevalence of obesity (over 26.3%).[4] This study analyzed data from subjects who were diagnosed with diabetes prior to COVID-19. They showed that obesity (body mass index [BMI] ≥30 kg/m2) is a significant risk factor for death (adjusted OR, 2.72), mechanical ventilation (1.87), and intensive care unit admission (2.41) after adjusting for age, sex, smoking status, and comorbidities. However, confounding factors still exist regarding the severity of diabetes. They obtained fasting blood glucose levels and prescription data for insulin and non-insulin therapies. Duration of diabetes, glycosylated hemoglobin level, and diabetic vascular complications should be assessed when categorizing the severity of diabetes. Furthermore, we need to consider the effects of antidiabetic medications. For example, recent national data from Korea demonstrated that the use of dipeptidyl peptidase-4 inhibitor was significantly associated with better clinical outcomes of COVID-19.[5] Therefore, further detailed analysis adjusting for diabetes status is necessary to determine a direct association between obesity and COVID-19 outcomes. A higher degree of obesity was related to higher all-cause mortality among individuals with type 2 diabetes.[6] During hospitalization for COVID-19, mortality was greater in severe obesity (BMI ≥40 kg/m2) even compared to subjects with BMI of 35–39.9 kg/m2.[7] This dose-dependent association between obesity and various outcomes of COVID-19 needs to be confirmed in subjects with diabetes and obesity. In addition, multi-ethnic group studies would give us more concrete data regarding the impact of obesity on health outcomes of COVID-19 and the generalizability of these findings across various populations.
  7 in total

1.  Body-mass index and mortality among adults with incident type 2 diabetes.

Authors:  Deirdre K Tobias; An Pan; Chandra L Jackson; Eilis J O'Reilly; Eric L Ding; Walter C Willett; JoAnn E Manson; Frank B Hu
Journal:  N Engl J Med       Date:  2014-01-16       Impact factor: 91.245

2.  Diabesity Associates with Poor COVID-19 Outcomes among Hospitalized Patients.

Authors:  Zeinab Nikniaz; Mohammad Hossein Somi; Masood Faghih Dinevari; Ali Taghizadieh; Leila Mokhtari
Journal:  J Obes Metab Syndr       Date:  2021-06-30

3.  Effects of a DPP-4 Inhibitor and RAS Blockade on Clinical Outcomes of Patients with Diabetes and COVID-19.

Authors:  Sang Youl Rhee; Jeongwoo Lee; Hyewon Nam; Dae-Sung Kyoung; Dong Wook Shin; Dae Jung Kim
Journal:  Diabetes Metab J       Date:  2021-03-05       Impact factor: 5.376

Review 4.  COVID-19 and metabolic disease: mechanisms and clinical management.

Authors:  Charlotte Steenblock; Peter E H Schwarz; Barbara Ludwig; Andreas Linkermann; Paul Zimmet; Konstantin Kulebyakin; Vsevolod A Tkachuk; Alexander G Markov; Hendrik Lehnert; Martin Hrabě de Angelis; Hannes Rietzsch; Roman N Rodionov; Kamlesh Khunti; David Hopkins; Andreas L Birkenfeld; Bernhard Boehm; Richard I G Holt; Jay S Skyler; J Hans DeVries; Eric Renard; Robert H Eckel; K George M M Alberti; Bruno Geloneze; Juliana C Chan; Jean Claude Mbanya; Henry C Onyegbutulem; Ambady Ramachandran; Abdul Basit; Mohamed Hassanein; Gavin Bewick; Giatgen A Spinas; Felix Beuschlein; Rüdiger Landgraf; Francesco Rubino; Geltrude Mingrone; Stefan R Bornstein
Journal:  Lancet Diabetes Endocrinol       Date:  2021-10-04       Impact factor: 32.069

5.  Obesity is a risk factor for developing critical condition in COVID-19 patients: A systematic review and meta-analysis.

Authors:  Mária Földi; Nelli Farkas; Szabolcs Kiss; Noémi Zádori; Szilárd Váncsa; Lajos Szakó; Fanni Dembrovszky; Margit Solymár; Eszter Bartalis; Zsolt Szakács; Petra Hartmann; Gabriella Pár; Bálint Erőss; Zsolt Molnár; Péter Hegyi; Andrea Szentesi
Journal:  Obes Rev       Date:  2020-07-19       Impact factor: 10.867

6.  Patterns of Obesity and Overweight in the Iranian Population: Findings of STEPs 2016.

Authors:  Shirin Djalalinia; Sahar Saeedi Moghaddam; Ali Sheidaei; Nazila Rezaei; Seyed Sina Naghibi Iravani; Mitra Modirian; Hossein Zokaei; Moein Yoosefi; Kimiya Gohari; Ahmad Kousha; Zhaleh Abdi; Shohreh Naderimagham; Ahmad Reza Soroush; Bagher Larijani; Farshad Farzadfar
Journal:  Front Endocrinol (Lausanne)       Date:  2020-02-26       Impact factor: 5.555

7.  COVID 19 in-hospital mortality, body mass index and obesity related conditions.

Authors:  Gursukhmandeep Sidhu; Rohan Samson; Sai Hariharan Nedunchezian; Sudesh Srivastav; Neal Dixit; Thierry H Le Jemtel
Journal:  J Diabetes Complications       Date:  2021-09-28       Impact factor: 2.852

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.